Mass High Tech reports "Avedro scores FDA advancement for eye disease treatment"

Mass High Tech reports "Avedro scores FDA advancement for eye disease treatment"

September 12, 2011

Waltham ophthalmologic device and pharmaceutical developer Avedro Inc. has been granted orphan drug designation by the U.S. Food and Drug Administration for its treatment of keratoconus, a degenerative eye disease found to be the leading cause of corneal transplants in the U.S.

Click logo to view full story.

 

Flagship Ventures Managing Partner Dr. Noubar Afeyan to Accept 2012 Technology Pioneer Award on Behalf of Joule Unlimited at WEF's "Summer Davos" Meeting

Flagship Ventures Managing Partner Dr. Noubar Afeyan to Accept 2012 Technology Pioneer Award on Behalf of Joule Unlimited at WEF's "Summer Davos" Meeting

September 13, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Flagship Ventures, a leading venture capital and venture creation firm specializing in life sciences and sustainable technology, today announced that Dr. Noubar Afeyan, Managing Partner and CEO of Flagship, will be presenting at the World Economic Forum's Annual Meeting of the New Champions 2011 in Dalian, China. The presentation, part of a panel entitled "From the Frontier: Solar Energy," will focus on Joule Unlimited, a Flagship portfolio company selected as a Technology Pioneer 2012 by the World Economic Forum.

Joule Unlimited, Inc.

Joule Named 2012 Technology Pioneer by World Economic Forum

Joule Named 2012 Technology Pioneer by World Economic Forum

September 1, 2011

Cambridge, Mass. – September 1, 2011 – Joule Unlimited Technologies, Inc. today announced its recognition as a member of the 2012 class of Technology Pioneers, a prestigious group of 25 industry-changing companies selected annually by the World Economic Forum. Joule was chosen from hundreds of nominees, recognized for the potential of its Helioculture™ technology to significantly impact both business and society through sustainable, cost-efficient and high-volume production of renewable fuels and chemicals.

BG Medicine, Inc.

BG Medicine, Inc. to Present at Baird's 2011 Health Care Conference

BG Medicine, Inc. to Present at Baird's 2011 Health Care Conference

September 1, 2011

WALTHAM, Mass., Sept. 1, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it will present at Baird's 2011 Health Care Conference on Thursday, September 8, 2011, at 12:45 p.m. Eastern Time. Pieter Muntendam, MD, President and CEO of the Company, will participate in a corporate presentation that will include highlights of galectin-3 studies recently presented at the European Society of Cardiology (ESC) Congress 2011.

TransMedics, Inc.

Los Angeles Times features TransMedics' Organ Care System

Los Angeles Times features TransMedics' Organ Care System

August 29, 2011

 

In a story titled, "Study tests if a warm heart makes a better transplant," the Los Angeles Times features Transmedics Organ Care System and its heart trial. 

Click below to view the full story: 

http://www.latimes.com/health/la-he-warm-heart-transplants-20110829,0,185265.story

BG Medicine, Inc.

Results of First Epidemiological Study of Galectin-3: Higher Levels Are Associated With an Increased Risk of Mortality

Results of First Epidemiological Study of Galectin-3: Higher Levels Are Associated With an Increased Risk of Mortality

August 30, 2011

Results Presented at European Society of Cardiology (ESC) Congress 2011

BG Medicine, Inc.

Preclinical Studies Support Galectin-3 as a New Drug Target in Heart Failure - Results Presented at European Society of Cardiology (ESC) Congress 2011

Preclinical Studies Support Galectin-3 as a New Drug Target in Heart Failure - Results Presented at European Society of Cardiology (ESC) Congress 2011

August 31, 2011

Helicos BioSciences Corporation

Helicos BioSciences Expands Its License with Arizona Technology Enterprises Covering Next Generation Sequencing; New Patents Continue to Issue

Helicos BioSciences Expands Its License with Arizona Technology Enterprises Covering Next Generation Sequencing; New Patents Continue to Issue

August 30, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Helicos BioSciences Corporation (OTCQB: HLCS.PK) announced today that it has amended its existing license with Arizona Technology Enterprises (AzTE) to include all activities that fall within the scope of, or constitute the practice of, the licensed patents, and gives Helicos full and unencumbered rights to the associated intellectual property.

BG Medicine, Inc.

Study Shows Galectin-3 Predicts Response to Statin Therapy in Chronic Heart Failure - Results Presented at European Society of Cardiology (ESC) Congress 2011

Study Shows Galectin-3 Predicts Response to Statin Therapy in Chronic Heart Failure - Results Presented at European Society of Cardiology (ESC) Congress 2011

August 29, 2011

WALTHAM, Mass., Aug. 29, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that results from a sub-study of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial were presented at the European Society of Cardiology (ESC) Congress 2011, in Paris, France.

Permeon Biologics Inc.

Permeon Biologics Boldly Go Where No MAb's Gone Before

Permeon Biologics Boldly Go Where No MAb's Gone Before

August 19, 2011

 

Excerpt from BioWorld Today

In terms of their specificity, biologics are magic bullets – or perhaps, magic magnets: Unlike bullets, they do not penetrate their target.

"There hasn't previously been an opportunity to address intracellular pathways with biological molecules," Alex Franzusoff told BioWorld Today. Franzusoff is CEO of Cambridge, Mass. based start-up Permeon Biologics, a company that hopes to change all that.

Click below to view the full BioWorld Today story: